Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for repotrectinib, a next-generation tyrosine...
Tubulis and Bristol Myers Squibb announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs).
Through the license agreement, Bristol Myers...
Lyvgen Biopharma, a leading innovative global biotech company dedicated to discovering, developing and commercializing first-in-class and best-in-class biotherapeutics for cancer, announced an open label,...
Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, announced a strategic collaboration and license...
BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, announced that it has entered into...
